BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Cullinan Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:24 pm Purchase |
2024-09-30 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 5,796,433 9.990% |
1,403,112 (+31.94%) |
Filing |
| 2024-02-14 10:16 am Sale |
2023-12-31 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 4,393,321 9.990% |
-3,115,738 (-41.49%) |
Filing |
| 2023-02-14 11:53 am Purchase |
2022-12-31 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 7,509,059 16.400% |
2,139,600 (+39.85%) |
Filing |
| 2022-02-14 1:23 pm Purchase |
2021-12-31 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 5,369,459 12.300% |
975,000 (+22.19%) |
Filing |
| 2021-12-20 4:52 pm Purchase |
2021-12-16 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 4,394,459 10.100% |
1,787,653 (+68.58%) |
Filing |
| 2021-11-08 5:20 pm Purchase |
2021-10-28 | 13G | Cullinan Oncology, Inc. CGEM |
BIOTECHNOLOGY VALUE FUND L P | 2,606,806 6.000% |
2,606,806 (New Position) |
Filing |